Luo ZD, Wang YF, Zhao YX, Yu LC, Li T, Fan YJ, Zeng SJ, Zhang YL, Zhang Y, Zhang X. Emerging roles of non-coding RNAs in colorectal cancer oxaliplatin resistance and liquid biopsy potential. World J Gastroenterol 2023; 29(1): 1-18 [PMID: 36683709 DOI: 10.3748/wjg.v29.i1.1]
Corresponding Author of This Article
Xin Zhang, MD, PhD, Additional Professor, Department of Clinical Laboratory, Qilu Hospital of Shandong University, Jinan 250012, Shandong Province, China. xinzhang@sdu.edu.cn
Research Domain of This Article
Research & Experimental Medicine
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Zheng-Dong Luo, Yi-Feng Wang, Yu-Xiao Zhao, Long-Chen Yu, Tian Li, Ying-Jing Fan, Shun-Jie Zeng, Yi Zhang, Xin Zhang, Department of Clinical Laboratory, Qilu Hospital of Shandong University, Shandong Engineering Research Center of Biomarker and Artificial Intelligence Application, Jinan 250012, Shandong Province, China
Yan-Li Zhang, Department of Clinical Laboratory, Shandong Provincial Third Hospital, Jinan 250012, Shandong Province, China
Author contributions: Zhang Y and Zhang X designed the manuscript; Luo ZD, Wang YF, and Zeng SJ drafted the manuscript; Zhao YX, Yu LC, Li T, and Fan YJ collected the information; Luo ZD, Zhang YL, and Zhang X revised the manuscript; Zhang YL and Zhang X coordinated the research and provided financial support; All authors read and approved the final manuscript.
Supported byThe Natural Science Foundation of Shandong Province, No. ZR2020MH238.
Conflict-of-interest statement: All authors declare that we have no other real or potential conflict of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xin Zhang, MD, PhD, Additional Professor, Department of Clinical Laboratory, Qilu Hospital of Shandong University, Jinan 250012, Shandong Province, China. xinzhang@sdu.edu.cn
Received: September 10, 2022 Peer-review started: September 10, 2022 First decision: September 29, 2022 Revised: October 11, 2022 Accepted: November 4, 2022 Article in press: November 4, 2022 Published online: January 7, 2023
Abstract
Colorectal cancer (CRC) is one of the most common malignancies of the digestive tract, with the annual incidence and mortality increasing consistently. Oxaliplatin-based chemotherapy is a preferred therapeutic regimen for patients with advanced CRC. However, most patients will inevitably develop resistance to oxaliplatin. Many studies have reported that non-coding RNAs (ncRNAs), such as microRNAs, long non-coding RNAs, and circular RNAs, are extensively involved in cancer progression. Moreover, emerging evidence has revealed that ncRNAs mediate chemoresistance to oxaliplatin by transcriptional and post-transcriptional regulation, and by epigenetic modification. In this review, we summarize the mechanisms by which ncRNAs regulate the initiation and development of CRC chemoresistance to oxaliplatin. Furthermore, we investigate the clinical application of ncRNAs as promising biomarkers for liquid CRC biopsy. This review provides new insights into overcoming oxaliplatin resistance in CRC by targeting ncRNAs.
Core Tip: Oxaliplatin has served as a first-line chemotherapy option for colorectal cancer (CRC). However, owing to congenital or acquired resistance, treatment failure is common in some patients with CRC. Abundant evidence has revealed that non-coding RNAs (ncRNAs) are extensively involved in cancer progression, including drug resistance. Specifically, ncRNAs mediate resistance to oxaliplatin by mediating drug carriers, tumor microenvironment, resistance-related signaling pathways, and patterns of cell death. Importantly, we investigated the potential and clinical application values of these ncRNAs as liquid biopsy markers for CRC.
